Stock Price Quote

HESTER BIOSCIENCES LTD.

NSE : HESTERBIOBSE : 524669ISIN CODE : INE782E01017Industry : Pharmaceuticals & DrugsHouse : Private
BSE1652.4028.8 (+1.77 %)
PREV CLOSE ( ) 1623.60
OPEN PRICE ( ) 1648.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 836
TODAY'S LOW / HIGH ( )1636.70 1670.70
52 WK LOW / HIGH ( )1292.9 1928.45
NSE1658.6028.45 (+1.75 %)
PREV CLOSE( ) 1630.15
OPEN PRICE ( ) 1638.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1658.60 (1)
VOLUME 6709
TODAY'S LOW / HIGH( ) 1630.20 1673.90
52 WK LOW / HIGH ( )1292.85 1939.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1987
Management Info
Bhupendra V Gandhi - Chairman Rajiv Gandhi - Managing Director
Registered Office

Address Pushpak’ 1st Floor,Panchvati Circle,Motila Hirabhai Road,
Ahmedabad,
Gujarat-380006

Phone 079 – 26445106

Email mail@hester.in

Website www.hester.in

Registrars Details
Link Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE

NEWS

09Apr Hester Biosciences informs about revis
Pursuant to Regulation 40(9) of SEBI (Listing Obligations and Disclosure..
04Apr Hester Biosciences informs about compl
Hester Biosciences has informed that it submitted the compliance Certifi..
02Feb Hester Biosciences informs about outco
Hester Biosciences has informed that Board of Directors, in their Meetin..
30Jan Hester Biosciences informs about discl
Hester Biosciences has informed that the exchange has received the discl..
30Jan Hester Biosciences informs about discl
Hester Biosciences has informed that the exchange has received the discl..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit64.75323.42
Gross Profit 86.13 439.24
Operating Profit 125.48602.09
Net Sales 655.052540

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE)
peergroup  827.60 (8.15%)
M.Cap ( in Cr)390.76
Mankind Pharma (BSE)
peergroup  2393.90 (2.40%)
M.Cap ( in Cr)95896.87
Torrent Pharma (BSE)
peergroup  2636.30 (1.76%)
M.Cap ( in Cr)89224.37
Ajanta Pharma (BSE)
peergroup  2135.80 (2.17%)
M.Cap ( in Cr)26893.07
Strides Pharma Scien (BSE)
peergroup  890.20 (5.24%)
M.Cap ( in Cr)8180.91

Shareholding Pattern

PROMOTERS 53.73%
NON-INSTITUTION 45.84%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Hester Biosciences Ltd.

Hester Biosciences Ltd. was incorporated in the year 1987. Its today's share price is 1652.4. Its current market capitalisation stands at Rs 1405.67 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2559.2 Cr and Total Income of Rs.2595.3 Cr. The company's management includes Jatin Trivedi, Anil Jain, Bhupendra V Gandhi, Ravin Gandhi, Sanjiv Gandhi, Priya Gandhi, Ameet Desai, Ashok Bhadakal, Sandhya Patel, Nina Gandhi, Rajiv Gandhi, Vinod Mali.

It is listed on the BSE with a BSE Code of 524669 , NSE with an NSE Symbol of HESTERBIO and ISIN of INE782E01017. It's Registered office is at Pushpak’ 1st Floor,Panchvati Circle,Motila Hirabhai RoadAhmedabad-380006, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Apaji Amin & Co LLP, Chandulal M Shah & Co, Shah Karia & Associates, Shah Narielwala & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.